Jiangsu Hengrui Medicine Co., Ltd.
Clinical trials sponsored by Jiangsu Hengrui Medicine Co., Ltd., explained in plain language.
-
New hope for tough pancreatic cancer: targeted drug combo enters final testing phase
Disease control Not yet recruitingThis study tests a new drug (HRS-4642) combined with chemotherapy for people with advanced pancreatic cancer that has a specific gene change called KRAS G12D. About 588 participants will receive either the new drug plus chemo or a placebo plus chemo. The goal is to see if the new…
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 03:16 UTC
-
New drug HRS-3005 targets tough blood cancers in early trial
Disease control Not yet recruitingThis early-stage study tests a new drug called HRS-3005 in 190 adults with B-cell blood cancers that have come back or not responded to treatment. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants must be in fairly good healt…
Phase: PHASE1 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated May 20, 2026 11:54 UTC